Quipt Home Medical Corp. (QIPT Q3 FY2024 earnings call

• Revenue growth: Fiscal Q3 2024 revenue was $64M, Y/Y +6.1%; nine months ended June 30, 2024, revenue was $193.3M, +21.4%.
• Impact of challenges: Faced challenges like end of Medicare 75-25 for lease, Change Healthcare cyberattack, and withdrawal of Medicare Advantage members, but saw year-over-year organic growth of 3% and flat sequential organic revenue growth.
• Sleep business: No negative impact from GLP-1s observed; referral patterns for new device setups consistent, resupply program strong. Data shows GLP-1s positively impact PAP therapy adherence.
• CID progress: Making progress in resolving civil investigative demand, with effective internal controls in place.
• Cyberattack impact: Focused on working through short-term working capital impact of Change Healthcare cyberattack.
• M&A pipeline: Pipeline growing with strategic opportunities, anticipating market dislocation from M&A activity to create organic growth opportunities.
• Capital management: Conservative balance sheet with 1.5 net leverage, committed to prudent capital management for sustainable growth.
• Strategic focus: Leveraging existing infrastructure and economies of scale, end-to-end respiratory solutions, operational efficiencies, and expansion into diabetes market with CGMs.

In fiscal Q3 2024, Quipt Home Medical reported revenue of $64 million, a 6.1% year-over-year increase, with adjusted EBITDA of $14.2 million and a 22.3% margin. For the nine months ended June 30, 2024, revenue was $193.3 million, a 21.4% increase compared to the prior period, and adjusted EBITDA was $44.5 million, representing 23% of revenue. Respiratory care accounts for approximately 80% of the product mix.

• Target 8%-10% annualized organic growth. - Focus on driving long-term organic growth, enhancing cash flow generation and margin. - Maintain financial flexibility to seize emerging opportunities. - Anticipate M&A activity to create organic growth opportunities. - Conservative balance sheet with 1.5 net leverage allows pursuit of strategic initiatives.

• Impact of Change Healthcare cyberattack on working capital. - Civil investigative demand (CID) uncertainty. - Impact of end of Medicare 75-25 for lease and withdrawal of Medicare Advantage members.

Q: How are you thinking about fourth quarter given challenges with 75-25 and Med Advantage?

A: Anticipating and working to overcome challenges, seeing volumes grow in the back half of the year.

Q: Reason for patient metrics increasing but no sequential revenue bump?

A: Impact of 75-25 rate cut and loss of decapitated insurance, with cross-selling abilities affected.

Q: Thoughts on bad debt?

A: Elevated 5% due to Change Healthcare impact, expecting to bring it back to previous levels as data comes in.

Q: Is current EBITDA margin level good going forward?

A: 22-plus EBITDA margin maintained despite challenges, operations supporting this margin.

Q: Achievability of free cash flow conversion target?

A: Will level out in next two quarters, having achieved in recent quarters.

Q: Valuation metrics on large industry deal and Quipt's acquisition target multiple?

A: Referenced deal had 6.3% EBITDA multiple; Quipt can acquire in 4%-5% EBITDA range prior to synergies.

Q: Insurance trends on GLP-1 impact and CPAP?

A: Not seeing trend of insurance requiring CPAP first before GLP-1s yet, but GLP-1s driving more people into healthcare system.